Noubar Afeyan discusses a new cancer vaccine from Merck and Moderna.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Combined with Keytruda immunotherapy, from Merck's laboratory, a new personalized messenger RNA treatment, developed by Moderna, has improved the survival without recurrence of patients with advanced melanoma.